TL;DR: Retatrutide (retatrutida in ES, retatrutid in DE) is the “triple agonist” — a single molecule that hits GLP-1, GIP, and glucagon receptors, which is why researchers nicknamed it the “King Kong of GLP-1s.” Research protocols use slow titration: a low start (often 2 mg-equivalent), stepping up roughly every four weeks. Vials ship in 5, 10, 15, 20, and 30 mg sizes, so the whole game is reconstitution math — turning “milligrams in the vial” into “units on the syringe.” Punch the numbers into the peptide calculator and it does the mg/mL and draw-volume work for you. This guide walks the logic so the output makes sense.
Why retatrutide is the “triple agonist”
Most incretin compounds are single (GLP-1) or dual (GLP-1 + GIP) agonists. Retatrutide adds a third target — the glucagon receptor — which drives energy expenditure on top of appetite modulation. In the Jastreboff et al. Phase 2 obesity trial (NEJM, 2023), the 12 mg weekly arm produced a mean body-weight change of about -24.2% at 48 weeks, with a quarter of participants passing the 30% mark. That magnitude is exactly why the “triple agonista” earned the King Kong reputation in research circles.
For the full mechanism breakdown, see what is retatrutide. Here we stay focused on the numbers.
The titration ladder: low start, step up
The single most-copied feature of the trial design is gradual dose escalation. Starting low and stepping up every four weeks gives receptors time to adapt, which is what kept most gastrointestinal effects mild-to-moderate. A representative research titration schedule looks like this:
Illustrative weekly research doses stepping up roughly every 4 weeks. Not a prescription.
The exact dosis de retatrutida a lab targets depends on the study question, but the shape is always the same: patient, incremental, four-week holds. For a deeper look at step logic and how to adjust cadence, read retatrutide dosing and titration.
Reconstitution: turning milligrams into mg/mL
Retatrutide ships as a lyophilized (freeze-dried) powder. You add bacteriostatic water (BAC), and the concentration you get is simply:
mg/mL = vial strength (mg) ÷ BAC water added (mL)
The convenient part: for a given target dose, the concentration is what determines how many units you draw. Here is how the five common vial sizes behave if you reconstitute each with 2 mL of BAC water:
You do not have to use 2 mL — that is just a clean reference. Higher-strength vials (20 and 30 mg) are often reconstituted with more water so the concentration stays workable and each draw lands on a readable spot on the syringe. That trade-off is exactly what the reconstitution calculator balances for you, and the high-strength handling quirks are covered in reconstitution for high-dose vials.
From mg/mL to units on the syringe
Research draws are measured in insulin units. On a standard U-100 syringe, 1 mL = 100 units. So:
mcg per unit = (mg/mL × 1000) ÷ 100
Worked example — a 10 mg vial reconstituted with 2 mL:
- Concentration: 10 ÷ 2 = 5 mg/mL = 5000 mcg/mL
- Per unit: 5000 ÷ 100 = 50 mcg per unit
- To draw a 2 mg (2000 mcg) dose: 2000 ÷ 50 = 40 units
Want a 4 mg step from the same vial? 4000 ÷ 50 = 80 units. An 8 mg step would be 160 units — past a single U-100 barrel, which is a signal you’d either split the draw or reconstitute at a higher concentration. This is the mcg/units conversion the calculator automates: enter vial strength, BAC volume, and target dose, and it returns mg/mL and the exact unit mark.
High-dose vials (20 and 30 mg)
The 20 and 30 mg vials exist because late-stage research doses climb. A 30 mg vial holds a lot of compound in a small cake, so the two decisions are: how much BAC to add, and how many doses you intend to pull per vial. Reconstitute a 30 mg vial with 3 mL and you get 10 mg/mL (100 mcg/unit) — a 12 mg draw is then 120 units, still a bit over one barrel. Bump to 1.5 mL and you’re at 20 mg/mL (200 mcg/unit), so 12 mg is 60 units. Same peptide, cleaner draw. The general reconstitution principles apply across every peptide — see the peptide reconstitution guide and peptide dosing 101.
Browsing vial options? The retatrutide 10mg page is the common reference size for the math above.
Frequently Asked Questions
What is the typical starting dose of retatrutide in research?
Trial protocols commonly begin around a 2 mg-equivalent weekly dose, then step up roughly every four weeks. The lower 2 mg start (versus 4 mg) was associated with fewer gastrointestinal events, which is why the mellow, patient ladder is the norm rather than jumping to a target dose.
How do I calculate mg/mL for a retatrutide vial?
Divide the vial’s milligram strength by the milliliters of bacteriostatic water you add. A 10 mg vial plus 2 mL BAC = 5 mg/mL. The reconstitution calculator does this instantly and also converts it to mcg-per-unit for your syringe.
How many units is a retatrutide dose?
It depends entirely on concentration. At 50 mcg per unit (a 10 mg vial in 2 mL), a 2 mg dose is 40 units. Change the water volume and the unit count changes proportionally — the calculator keeps it exact.
Why is retatrutide called the “King Kong of GLP-1s”?
Because it’s a triple agonist — GLP-1, GIP, and glucagon receptors at once — and produced larger mean weight changes in Phase 2 (about 24% at 48 weeks) than single or dual agonists, so researchers gave it the oversized nickname.
Can I reconstitute a 30mg vial the same way as a 10mg vial?
The formula is identical, but high-strength vials are usually given more BAC water so each draw stays on a readable part of the syringe. See reconstitution for high-dose vials for the concentration trade-offs.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 2023;389:514-526. doi:10.1056/NEJMoa2301972.
- Sanyal AJ, Kaplan LM, Frías JP, et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature Medicine, 2024;30:2037-2048.
- American Diabetes Association. “Novel Agent Retatrutide Results in Substantial Weight Reduction” — 83rd Scientific Sessions late-breaking symposium press summary, 2023.
- Coskun T, Urva S, Roell WC, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: preclinical and Phase 1 studies.” Cell Metabolism, 2022;34(9):1234-1247.
This article is a research and educational reference only; retatrutide is not an approved medicine, this is not medical advice, and it is not for human consumption.